Skip to content
InnocsAI
-
Liminatus Pharma to acquire InnocsAI in US$320M share-based CAR-T oncology deal
Liminatus went public in 2022 through a SPAC merger and initially highlighted several immune-modulating therapies originating from research collaborations in the United States and South Korea.